Teva Pharmaceutical Industries (TEVA) filed a registration statement with the US Securities and Exchange Commission Friday for the sale of securities by the company and its finance subsidiaries.
The prospectus includes American depositary shares each representing one ordinary share, debt securities, purchase contracts and units.
Proceeds from the sale of securities will be used for general corporate purposes including working capital, investments in, or extensions of credit to Teva's units and repay debt, according to the filing.